COVID-19 vaccination and systemic autoimmune rheumatic diseases: No evidence of disproportionately increased reporting in VAERS
In a large national pharmacovigilance dataset, COVID-19 vaccines were not associated with a disproportionate increase in reports of any SARD. These results support the favorable safety profile of COVID-19 vaccines with respect to autoimmune rheumatic events, while highlighting the value of ongoing post-marketing surveillance for rare immune-mediated reactions.
Authors
- F. Ursini (ORCID: https://orcid.org/0000-0001-9442-7897)
- Piero Ruscitti (ORCID: https://orcid.org/0000-0003-3487-8551)
- Jacopo Ciaffi (ORCID: https://orcid.org/0000-0002-9446-7351)
- G Torrigiani (ORCID: https://orcid.org/0009-0009-9987-7657)
- Antonella Zambon
Institutions
- University of L'Aquila (IT)
- Quantitative BioSciences (US)
- Istituto Ortopedico Rizzoli (IT)
- IRCCS Istituto Auxologico Italiano (IT)
- University of Bologna (IT)
Publication Details
- Journal
- Seminars in Arthritis and Rheumatism
- Published
- 2026-01-02
- DOI
- https://doi.org/10.1016/j.semarthrit.2025.152911
- Primary Topic
- SARS-CoV-2 and COVID-19 Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00